Braxia Scientific Corp.: Difference between revisions
>Chris Created page with "Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. It is also involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and developing ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. In addition, the company owns and operates multidisciplinary clinics for th..." |
No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
== Summary == | |||
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. It is also involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and developing ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. In addition, the company owns and operates multidisciplinary clinics for the treatment of mental health disorders. Braxia Scientific Corp. is headquartered in Mississauga, Ontario. | Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. It is also involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and developing ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. In addition, the company owns and operates multidisciplinary clinics for the treatment of mental health disorders. Braxia Scientific Corp. is headquartered in Mississauga, Ontario. | ||
__INDEX__ | |||
Latest revision as of 16:38, 19 August 2022
Summary edit edit source
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. It is also involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and developing ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. In addition, the company owns and operates multidisciplinary clinics for the treatment of mental health disorders. Braxia Scientific Corp. is headquartered in Mississauga, Ontario.